Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies

Journal of Clinical Pharmacology

Volumn 56, Issue 2, 2016, Pages 143-151

  Liu, Lichuan ^a   Bello, Akintunde ^b   Dresser, Mark J ^a   Heald, Donald ^c   Komjathy, Steven Ferenc ^d   O'Mara, Edward ^e   Rogge, Mark ^f   Stoch, S Aubrey ^g   Robertson, Sarah M ^h  

^a GENENTECH INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d ELI LILLY AND COMPANY   (United States)

^e CELGENE CORPORATION   (United States)

^f BIOGEN   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h VERTEX PHARMACEUTICALS   (United States)

Author keywords

CYP3A; drug interaction; itraconazole; ketoconazole

Indexed keywords

CYCLOSPORIN; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; TACROLIMUS; TRIAZOLAM; ANTIFUNGAL AGENT;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELIMINATION HALF-LIFE; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; PRACTICE GUIDELINE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT INDICATION; CLINICAL TRIAL (TOPIC); DRUG INTERACTION;

ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; ITRACONAZOLE; KETOCONAZOLE;

EID: 84956783040     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.562     Document Type: Article

References (45)

1. Smith EB, Henry JC,. Ketoconazole: an orally effective antifungal agent. Mechanism of action, pharmacology, clinical efficacy and adverse effects. Pharmacotherapy. 1984; 4 (4): 199-204.
2. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm.
3. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/07/news-detail-001855.jsp&mid=WC0b01ac058004d5c1.
4. Gibbs MA, Thummel KE, Shen DD, Kunze KL,. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos. 1999; 27 (2): 180-187.
5. Zhao P, Ragueneau-Majlessi I, Zhang L, et al., Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol. 2009; 49 (3): 351-359.
6. FDA advises against using oral ketoconazole in drug interaction studies due to serious potential side effects. http://www.fda.gov/Drugs/DrugSafety/ucm371017.htm.
7. Deeks ED,. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014; 74 (2): 195-206.
8. Greenblatt DJ, Harmatz JS,. Ritonavir is the best alternative to ketoconazole as index inhibitor of Cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol. 2015; doi: 10.1111/bcp.12668.
9. Kirby BJ, Collier AC, Kharasch ED, et al., Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos. 2011; 39 (12): 2329-2337.
10. Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD,. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther. 2014; 95 (5): 473-476.
11. Krishna G, Ma L, Prasad P, Moton A, Martinho M, O'Mara E., Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol. 2012; 8 (1): 1-10.
12. Krishna G, Moton A, Ma L, et al., Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther. 2009; 31 (2): 286-298.
13. Seithel A, Eberl S, Singer K, et al., The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1 B3. Drug Metab Dispos. 2007; 35 (5): 779-786.
14. Pappas PG, Kauffman CA, Andes D, et al., Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48: 503-535.
15. Hainer BL,. Dermatophyte infections. Am Fam Physician. 2003; 67 (1): 101-108.
16. Nolting SK, Gupta A, Doncker PD, Jacko ML, Moskovitz BL,. Continuous itraconazole treatment for onychomycosis and dermatomycosis: an overview of safety. Eur J Dermatol. 1999; 9 (7): 540-543.
17. Gupta A, Lambert J, Revuz J, Shear N., Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur J Dermatol. 2001; 11 (1): 6-10.
18. Gupta AK, Chwetzoff E, Del Rosso J, Baran R., Hepatic safety of itraconazole. J Cutan Med Surg. 2002; 6 (3): 210-213.
19. Haneke E, Abeck D, Ring J., Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. Mycoses. 1998; 41 (11-12): 521-527.
20. Queiroz-Telles F, Purim KS, Boguszewski CL, Afonso FC, Graf H., Adrenal response to corticotrophin and testosterone during long-term therapy with itraconazole in patients with chromoblastomycosis. J Antimicrob Chemother. 1997; 40 (6): 899-902.
21. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR,. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother. 1991; 35 (4): 707-713.
22. Sung DJ, Kim JG, Won KJ, et al., Blockade of K+ and Ca2+ channels by azole antifungal agents in neonatal rat ventricular myocytes. Biol Pharm Bull. 2012; 35 (9): 1469-1475.
23. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR,. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol. 1993; 33 (12): 1201-1206.
24. Heykants J, Van Peer A, Van de Velde V, et al., The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;(32 Suppl 1): 67-87.
25. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG,. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988; 32 (9): 1310-1313.
26. Templeton IE, Thummel KE, Kharasch ED, et al., Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther. 2008; 83 (1): 77-85.
27. Barone JA, Koh JG, Bierman RH, et al., Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993; 37 (4): 778-784.
28. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE,. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos. 2004; 32 (10): 1121-1131.
29. Poirier JM, Cheymol G., Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet. 1998; 35 (6): 461-473.
30. Banerjee R, Leaver N, Lyster H, Banner NR,. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc. 2001; 33 (1-2): 1600-1602.
31. Woestenborghs R, Lorreyne W, Heykants J., Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr. 1987; 413: 332-337.
32. Arredondo G, Calvo R, Marcos F, Martinez-Jorda R, Suarez E., Protein binding of itraconazole and fluconazole in patients with cancer. Int J Clin Pharmacol Ther. 1995; 33 (8): 449-452.
33. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW,. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002; 46 (1): 160-165.
34. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ,. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998; 54 (1): 53-58.
35. Olkkola KT, Ahonen J, Neuvonen PJ,. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996; 82 (3): 511-516.
36. Barone JA, Moskovitz BL, Guarnieri J, et al., Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy. 1998; 18 (2): 295-301.
37. Barone JA, Moskovitz BL, Guarnieri J, et al., Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother. 1998; 42 (7): 1862-1865.
38. Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N., Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther. 2010; 88 (4): 499-505.
39. Kivisto KT, Kantola T, Neuvonen PJ,. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998; 46 (1): 49-53.
40. Jalava KM, Olkkola KT, Neuvonen PJ,. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther. 1997; 61 (4): 410-415.
41. Neuvonen PJ, Varhe A, Olkkola KT,. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther. 1996; 60 (3): 326-331.
42. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ,. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003; 73 (3): 192-198.
43. Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M., Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol. 2011; 51 (3): 359-367.
44. Nara M, Takahashi N, Miura M, et al., Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants. Eur J Clin Pharmacol. 2013; 69 (6): 1321-1329.
45. Shitrit D, Ollech JE, Ollech A, et al., Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplantation. 2005; 24 (12): 2148-2152.